Uploaded July 2023 | Updated September 2026, 1 hour ago
The risks associated with COVID-19 infection are higher for immunocompromised individuals and those over 65 than the general public. ImmunoCARE is an innovative research project to study whether repeated at-home tests, on-demand telemedicine, and quick delivery of medication for those who test positive for COVID-19 can reduce COVID-19 severity in immunocompromised people.
ImmunoCARE is a joint research project from Scripps Research – a renowned biomedical research organization — and Cue Health, a leading health care technology company that develops portable diagnostic tests for at-home use.
Learn more:
https://immunocare.scripps.edu/
The risks associated with COVID-19 infection are higher for immunocompromised individuals and those over 65 than the general public. ImmunoCARE is an innovative research project to study whether repeated at-home tests, on-demand telemedicine, and quick delivery of medication for those who test positive for COVID-19 can reduce COVID-19 severity in immunocompromised people.
ImmunoCARE is a joint research project from Scripps Research – a renowned biomedical research organization — and Cue Health, a leading health care technology company that develops portable diagnostic tests for at-home use.
Learn more:
https://immunocare.scripps.edu/
